EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Single‐Cell Computational Frameworks for Quantifying BET Bromodomain Inhibitor Resistance and Screening Re‐Sensitizer Drugs in Triple‐Negative Breast Cancer

Haizhou Liu, Mengqin Yuan, Yini Shang, Jiahao Chen, Fei Hou, Lihong Wang, Wei Jiang iD

Advanced Science · 2026

DOI: 10.1002/advs.202513246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Haizhou Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Key Laboratory of Tumor Immunotherapy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm, Antineoplastic Agents, Single-Cell Analysis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province of China, Fujian Provincial Health and Wellness Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) is an aggressive subtype characterized by rapid proliferation and a great propensity for metastasis. Therapeutic options for TNBC remain limited due to the absence of targetable hormone receptors. While BET bromodomain inhibitors (BBDIs) exhibit promising anticancer potential, the emergence of drug resistance presents a major challenge. Here, through leveraging single‐cell RNA sequencing (scRNA‐seq) data across continuous states of BBDI treatment in TNBC, this study conducts an extensive investigation into BBDI resistance, and develops two computational frameworks, FR20 and D‐FR20, to quantify BBDI resistance at single‐cell resolution and to screen potential BBDI re‐sensitizer drugs, respectively. The accuracy and scalability of FR20 are confirmed through rigorous evaluation in nine independent datasets. In addition, cellular dynamic changes and ferroptosis inhibition are revealed in the evolution of BBDI resistance. Experimental validation demonstrates that GPX 4 overexpression significantly reduces drug sensitivity in TNBC cells. Furthermore, in vitro and in vivo experiments validate the ability of the small molecule filgotinib, identified by D‐FR20, to re‐sensitize BBDI and effectively eliminate resistant TNBC cells. Collectively, this study provides two computational frameworks for predicting BBDI resistance and candidate re‐sensitizer, as well as demonstrates the roles of ferroptosis in BBDI resistance, offering a promising avenue for TNBC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsDrug Resistance, NeoplasmAntineoplastic AgentsSingle-Cell AnalysisHumansFemaleAnimalsCell Line, TumorBromodomain Containing ProteinsMiceProteins

Stichwörter der Autor:innen

BET bromodomain inhibitordrug resistanceferroptosisscRNA‐seqtriple‐negative breast cancer

Substanzen

Antineoplastic AgentsBromodomain Containing Proteinsbromodomain and extra-terminal domain protein, humanProteins

Autor:innen und Institutionen

  • Fujian Key Laboratory of Tumor Immunotherapy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Department of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, China.
  • Department of Pathophysiology, School of Medicine, Southeast University, Nanjing, China.
  • Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing, China.

ORCID-Profile: Wei Jiang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Fujian Province of China
  • Fujian Provincial Health and Wellness Science and Technology Plan Project
  • Joint Funds for the Innovation of Science and Technology, Fujian Province

Zitieren

APA

Liu, H., Yuan, M., Shang, Y., Chen, J., Hou, F., Wang, L., & Jiang, W. (2026). Single‐Cell Computational Frameworks for Quantifying BET Bromodomain Inhibitor Resistance and Screening Re‐Sensitizer Drugs in Triple‐Negative Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202513246

Vancouver

Liu H, Yuan M, Shang Y, Chen J, Hou F, Wang L, et al. Single‐Cell Computational Frameworks for Quantifying BET Bromodomain Inhibitor Resistance and Screening Re‐Sensitizer Drugs in Triple‐Negative Breast Cancer. Advanced Science. 2026. doi:10.1002/advs.202513246

BibTeX
@article{Liu2026,
  author = {Liu, Haizhou and Yuan, Mengqin and Shang, Yini and Chen, Jiahao and Hou, Fei and Wang, Lihong and Jiang, Wei},
  title = {Single‐Cell Computational Frameworks for Quantifying BET Bromodomain Inhibitor Resistance and Screening Re‐Sensitizer Drugs in Triple‐Negative Breast Cancer},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202513246}
}
Kostenlos starten →